GITNUX MARKETDATA REPORT 2024

Acute Myeloid Leukemia Industry Statistics

The Acute Myeloid Leukemia industry faces challenges in terms of low survival rates, high treatment costs, and a need for more research and development efforts to improve patient outcomes.

Last Updated: June 22, 2024

Written & Summarized by: Jannik Lindner

How we write

In this post, we will explore various statistics surrounding acute myeloid leukemia (AML) – a type of cancer that impacts thousands of individuals each year. From diagnosis rates and survival probabilities to market values and demographic trends, these figures offer a comprehensive overview of the current landscape of AML. Join us as we dive into the data that sheds light on this critical aspect of healthcare.

Statistic 1

"About 20,000 cases of acute myeloid leukemia (AML) are diagnosed each year in the United States."

Statistic 2

"The survival rates for AML vary by age, with a five-year survival rate of 26.6% for all ages."

Statistic 3

"The median age at diagnosis for acute myeloid leukemia is 68 years old."

Statistic 4

"The global acute myeloid leukemia market size was valued at USD 702.4 million in 2019"

Statistic 5

"The acute myeloid leukemia industry is anticipated to expand at a compound annual growth rate (CAGR) of 12.3% from 2020 to 2027."

Statistic 6

"Acute Promyelocytic Leukemia (APL), a subtype of AML, accounts for about 10% of AML cases."

Statistic 7

"Acute Myeloid Leukemia (AML) Market set to reach USD 1.5 billion by 2026."

Statistic 8

"Among industrialised countries, Australia has the highest incidence of Acute Myeloid Leukemia (AML)."

Statistic 9

"The prevalence of AML is slightly higher in men than in women."

Statistic 10

"The risk of developing AML increases with age, with a spike seen after age 65."

Statistic 11

"Racial disparities in AML incidence and outcome have been observed, with incidence rates being highest among whites."

Statistic 12

"Treatment of AML is expensive, with an estimated average cost of care being $60,000 within the first year of diagnosis."

Statistic 13

"In 2017, there were around 62,000 people living with AML in the United States."

Statistic 14

"By 2028, global therapeutic development in AML is set to exceed 3.7 billion."

Statistic 15

"In studies, survival rates for AML were lower among patients who live in rural compared to urban areas."

Statistic 16

"Worldwide, the incidence of AML is around 4 cases per 100,000 people annually."

Statistic 17

"More than 10,000 people each year die from AML in the United States."

Statistic 18

"Only 24% of AML patients aged 65 and older survive more than one year after diagnosis."

The statistics presented highlight the significant impact of acute myeloid leukemia (AML) on individuals and the healthcare industry. With around 20,000 new cases diagnosed annually in the United States, the disease poses a considerable burden, particularly among older populations, with a median age at diagnosis of 68 years old. Survival rates remain relatively low, with only 26.6% of patients surviving five years across all age groups. The industry is rapidly growing, with a projected market size of USD 1.5 billion by 2026 and a compound annual growth rate of 12.3% from 2020 to 2027. Disparities in incidence rates based on age, gender, and race underscore the complex nature of AML, while the high cost of treatment further compounds the challenges faced by patients. The evolving landscape of therapeutic development offers hope for the future, but improvements in survival rates and access to care are crucial to addressing the significant mortality associated with this disease.

Jannik Lindner

Jannik is the Co-Founder of Gitnux and has been working in the digital space since 2016. He is specialized in content and tech.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.